Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
MDCX
$1.17
$
Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.
Beta
-1.713
Average Volume
Market Cap
Last Dividend
CIK
0001997296
ISIN
CA58471K2020
CUSIP
CEO
Raza Bokhari
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
12
IPO Date
2024-11-15
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| FTSE 100 Live: London stocks outperform as pound falls on unemployment spike | FTSE rises 23 points to 10,497 UK unemployment rises to 5.2% Pound falls as investors expect sooner BoE rate cut IHG impresses with final results and... | Proactive Investors - Finance | 2026-02-17 05:43:00 |
| Pinewood plunges after Apax walks away | Shares in Pinewood Technologies, known as Pinewood.AI, plunged more than 29% to 308.06p after Apax Partners put out a statement on Friday evening to reveal... | Proactive Investors - Finance | 2026-02-16 04:16:00 |
| Medicus Pharma's Teverelix Phase 2b trial cleared by FDA - ICYMI | Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the FDA's clearance to begin a Phase 2b dose optimization study for Teverelix, the company's next-generation GnRH antagonist targeting advanced prostate cancer. Proactive: All right. | Proactive Investors | 2026-02-14 11:50:12 |
| Medicus Pharma’s Teverelix Phase 2b trial cleared by FDA - ICYMI | Medicus Pharma (NASDAQ:MDCX) CEO Raza Bokhari talked with Proactive about the FDA's clearance to begin a Phase 2b dose optimization study for Teverelix, the... | Proactive Investors - Finance | 2026-02-14 06:19:00 |
| Medicus Pharma on Bloomberg World | Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Matt Miller from Bloomberg World for a live interview on February 10, 2026. | Accesswire | 2026-02-12 07:30:00 |
| Medicus Pharma receives FDA clearance to proceed with Phase 2b prostate cacner study | Medicus Pharma (NASDAQ:MDCX) announced that it has received “study may proceed” clearance from the US Food and Drug Administration (FDA) to initiate a Phase 2b dose-optimization study of Teverelix, its investigational long-acting gonadotropin-releasing hormone (GnRH) antagonist, in men with advanced prostate cancer and elevated cardiovascular risk. The open-label Phase 2b trial is expected to enroll 40 patients who are candidates for androgen deprivation therapy. | Proactive Investors | 2026-02-10 09:36:03 |
| Medicus Pharma Receives FDA “Study May Proceed” Clearance For Teverelix® Phase 2b Study in Advanced Prostate Cancer Patients with High Cardiovascular Risk | The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity The Company is developing Teverelix® as a best-in-class market product for advanced prostate cancer patients with high CV risk and a first in class product for Acute Urinary Retention Relapse prevention (AURr) collectively representing ~US$6 billion in potential market opportunity | GlobeNewsWire | 2026-02-10 07:30:00 |
| Medicus Pharma marks Nasdaq milestone as it advances Phase 2 clinical programs | Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the Opening Bell at the Nasdaq MarketSite in New York's Times Square. CEO Dr Raza Bokhari said the company was honored with the opportunity, describing the milestone as a reflection of Medicus' progress since going public and its continued focus on disciplined execution across a streamlined and strategically selected clinical portfolio. | Proactive Investors | 2026-01-23 08:56:32 |
| Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Steve Darling from Proactive https://youtu.be/8EErx6aQEXs to announce that the company was honored with the opportunity to ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square, marking the one-year anniversary of Medicus' listing on the Nasdaq exchange. | Accesswire | 2026-01-23 07:30:00 |
| TikTok parent ByteDance finalizes US joint venture deal to avoid ban | ByteDance, the Chinese owner of TikTok, announced Thursday that it has finalized a deal to create a majority American-owned joint venture to operate the... | Proactive Investors - Finance | 2026-01-23 06:19:00 |
| Medicus Pharma marks Nasdaq milestone as it advances Phase 2 clinical programs | Medicus Pharma (NASDAQ:MDCX) has marked the one-year anniversary of its Nasdaq listing on Thursday by ringing the Opening Bell at the Nasdaq MarketSite in... | Proactive Investors - Finance | 2026-01-23 03:52:00 |
| Medicus Pharma lowers royalty burden on prostate cancer drug Teverelix | Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization LifeArc, reducing future royalties tied to the experimental drug Teverelix, a move the company said improves the asset's long-term commercial profile. Under the revised agreement, royalties payable on worldwide net sales of Teverelix have been cut to 2% from about 4%, with the royalty term clarified on a country-by-country basis, Medicus said. | Proactive Investors | 2026-01-22 08:42:55 |
| Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile | Amendment reduces and simplifies royalty structure on Teverelix ® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix ® as a first in class market product for Acute Urinary Retention Relapse prevention (AURr) and best in class for prostate cancer patients with high CV risk collectively representing ~US$6 billion in potential market opportunity PHILADELPHIA, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its subsidiary, Antev Ltd. | GlobeNewsWire | 2026-01-22 07:30:00 |
| Medicus Pharma lowers royalty burden on prostate cancer drug Teverelix | Medicus Pharma (NASDAQ:MDCX) said on Thursday its subsidiary Antev Ltd has amended a licensing agreement with UK-based medical research organization... | Proactive Investors - Finance | 2026-01-22 03:41:00 |
| Coking coal upside seen by UBS as prices hit year's high | UBS has upgraded its 2026 benchmark price forecast for premium low vol coking coal by 17% to $235 per tonne, citing ongoing supply disruptions and strong... | Proactive Investors - Finance | 2026-01-20 10:42:00 |
| Medicus Pharma marks one-year Nasdaq anniversary, advances Phase 2 therapeutics | Medicus Pharma (NASDAQ:MDCX) will ring the Nasdaq Opening Bell on January 22, marking its one-year Nasdaq anniversary. The biotech company focuses on advancing novel therapeutics, including SkinJect for basal cell carcinoma ($2 billion market) and Teverelix for advanced prostate cancer ($6 billion market). | Proactive Investors | 2026-01-20 10:25:16 |
| Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce it will ring the Nasdaq Opening Bell at the Nasdaq MarketSite in New York's Times Square on Thursday, January 22, 2026, in recognition of the Company's one-year anniversary as a Nasdaq-listed company. | GlobeNewsWire | 2026-01-20 07:30:00 |
| Medicus Pharma marks one-year Nasdaq anniversary, advances Phase 2 therapeutics | Medicus Pharma (NASDAQ:MDCX) will ring the Nasdaq Opening Bell on January 22, marking its one-year Nasdaq anniversary. The biotech company focuses on... | Proactive Investors - Finance | 2026-01-20 05:09:00 |
| Medicus Pharma Ltd (NASDAQ:MDCX) Given Consensus Rating of “Moderate Buy” by Brokerages | Shares of Medicus Pharma Ltd (NASDAQ: MDCX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five research firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and | Defense World | 2026-01-20 04:39:06 |
| Analysts look to 'cyclicals' as inflection point approaches | In terms of sector themes, JP Morgan is sticking with “the cyclicals”, arguing the backdrop for 2026 looks increasingly supportive as the growth–inflation... | Proactive Investors - Finance | 2026-01-12 10:06:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| EFFECT | 2026-02-04 | 2026-02-05 | View Filing |
| S-3 | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G/A | 2026-01-05 | 2026-01-05 | View Filing |
| 424B5 | 2026-01-02 | 2026-01-02 | View Filing |
| EFFECT | 2025-12-31 | 2026-01-02 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 253G2 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 424B3 | 2025-12-30 | 2025-12-30 | View Filing |
| 8-K | 2025-12-30 | 2025-12-30 | View Filing |
| S-3 | 2025-12-30 | 2025-12-29 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 4 | 2025-12-18 | 2025-12-18 | View Filing |
| 253G2 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 424B3 | 2025-12-08 | 2025-12-08 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| EFFECT | 2025-12-04 | 2025-12-05 | View Filing |
| 424B3 | 2025-12-05 | 2025-12-04 | View Filing |
| 253G2 | 2025-12-01 | 2025-12-01 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| 424B3 | 2025-12-01 | 2025-12-01 | View Filing |
| 8-K | 2025-12-01 | 2025-12-01 | View Filing |
| S-1 | 2025-11-19 | 2025-11-19 | View Filing |
| EFFECT | 2025-11-14 | 2025-11-17 | View Filing |
| EFFECT | 2025-11-14 | 2025-11-17 | View Filing |
| 424B3 | 2025-11-17 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-17 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-17 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-17 | 2025-11-14 | View Filing |
| 424B3 | 2025-11-17 | 2025-11-14 | View Filing |
| 8-K | 2025-11-14 | 2025-11-14 | View Filing |
| S-8 | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-14 | 2025-11-14 | View Filing |
| 424B3 | 2025-10-17 | 2025-10-17 | View Filing |
| 424B3 | 2025-10-17 | 2025-10-17 | View Filing |
| 253G2 | 2025-10-17 | 2025-10-17 | View Filing |
| 424B3 | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-10-17 | 2025-10-17 | View Filing |
| S-1 | 2025-09-29 | 2025-09-29 | View Filing |
| S-1 | 2025-09-29 | 2025-09-29 | View Filing |
| 424B3 | 2025-09-18 | 2025-09-18 | View Filing |
| 424B3 | 2025-09-18 | 2025-09-18 | View Filing |
| 253G2 | 2025-09-18 | 2025-09-18 | View Filing |
| 424B3 | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| 424B3 | 2025-09-15 | 2025-09-15 | View Filing |
| 424B3 | 2025-09-15 | 2025-09-15 | View Filing |
| 253G2 | 2025-09-15 | 2025-09-15 | View Filing |
| 424B3 | 2025-09-15 | 2025-09-15 | View Filing |
| 8-K | 2025-09-12 | 2025-09-12 | View Filing |
| 3 | 2025-09-08 | 2025-09-08 | View Filing |
| 424B3 | 2025-09-02 | 2025-09-02 | View Filing |
| 424B3 | 2025-09-02 | 2025-09-02 | View Filing |
| 424B3 | 2025-09-02 | 2025-09-02 | View Filing |
| 253G2 | 2025-09-02 | 2025-09-02 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| 424B3 | 2025-08-22 | 2025-08-22 | View Filing |
| 424B3 | 2025-08-22 | 2025-08-22 | View Filing |
| 253G2 | 2025-08-22 | 2025-08-22 | View Filing |
| 424B3 | 2025-08-22 | 2025-08-22 | View Filing |
| 8-K | 2025-08-22 | 2025-08-22 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 4 | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-12 | 2025-08-12 | View Filing |
| SC 13G/A | 2025-08-12 | 2025-08-12 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-11 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-11 | View Filing |
| 253G2 | 2025-08-12 | 2025-08-11 | View Filing |
| 424B3 | 2025-08-12 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 3/A | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-04 | 2025-08-04 | View Filing |
| 3 | 2025-07-31 | 2025-07-31 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
| 4 | 2025-07-24 | 2025-07-24 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Choppiness Index Strategy | 7.99% | 1.06 | 39 | 1.07 | 0.89 | 1.87 |
| Adaptive Wave | 7.64% | 1 | 1 | 0.74 | 0.54 | 1.52 |
| Neural Forcast | 6.71% | 1.11 | 20 | 1.42 | 0 | 0.6 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |